Novartis' consumer health division, which includes CIBA Vision, reported sales growth of 9 percent to $1.7 billion in the 1st quarter. In local currencies, turnover for this segment was up by 6 percent. The company said that CIBA Vision made progress in the quarter in improving supplies of contact lens, after a shortage at the end of 2006, and benefited from better lens care supplies. Novartis' total sales rose by 18 percent to $9.8 billion, and were up by 15 percent in local currencies. Net profit grew by 11 percent to $2.17 billion, including an extraordinary charge of $52 million for the recall of a drug, Zelnorm, at the request of the U.S. Food & Drug Administration.